Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.lumithera.com › category › press-releasesPress Releases and Events - LumiThera

   www.lumithera.com › category › press-releases

   • Zapisane w pamięci cache

   SEATTLE, March 22, 2022 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced positive findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular (dry) Age-Related Macular Degeneration (AMD) subjects treated with ...

2. www.lumithera.com › lumithera-provides-update-on-fda-review-of-valeda-treatmentLumiThera Provides Update on FDA Review of Valeda Treatment for...

   www.lumithera.com › lumithera-provides-update-on-fda-review-of-valeda-treatment

   • Zapisane w pamięci cache

   4 sty 2024 · SEATTLE– (BUSINESS WIRE)–LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced an update on the regulatory status of the Valeda® Light Delivery System.

3. www.lumithera.com › lumithera-presents-us-lightsite-iii-trial-data-showingLumiThera Presents US LIGHTSITE III Trial Data Showing...

   www.lumithera.com › lumithera-presents-us-lightsite-iii-trial-data-showing

   • Zapisane w pamięci cache

   22 cze 2022 · SEATTLE, June 22, 2022 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced detailed findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular (dry) Age-Related Macular Degeneration (AMD) subjects treated with ...

4. finance.yahoo.com › news › lumithera-announces-initiation-eurolight-registryLumiThera Announces Initiation of EUROLIGHT Registry Study to...

   finance.yahoo.com › news › lumithera-announces-initiation-eurolight-registry

   • Zapisane w pamięci cache

   16 sty 2024 · SEATTLE, January 16, 2024--LumiThera Initiates EUROLIGHT Registry Study to Evaluate Long-term Benefits of Valeda® Treatments in Dry Age-Related Macular Degeneration Patients.

5. www.businesswire.com › news › homeLumiThera Provides Update on FDA Review of Valeda ... - Business...

   www.businesswire.com › news › home

   • Zapisane w pamięci cache

   3 sty 2024 · SEATTLE-- ( BUSINESS WIRE )--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced an update on the regulatory status...

6. www.prnewswire.com › news-releases › lumithera-announces-us-lightsite-iii-clinicalLumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary...

   www.prnewswire.com › news-releases › lumithera-announces-us-lightsite-iii-clinical

   • Zapisane w pamięci cache

   22 mar 2022 · SEATTLE, March 22, 2022 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced...

7. www.prnewswire.com › news-releases › lumithera-presents-us-lightsite-iii-trialLumiThera Presents US LIGHTSITE III Trial Data Showing...

   www.prnewswire.com › news-releases › lumithera-presents-us-lightsite-iii-trial

   • Zapisane w pamięci cache

   22 cze 2022 · SEATTLE, June 22, 2022 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced...